Zoster‑related eye inflammation (keratitis) - Causes, Treatment & When to See a Doctor

```html

What is Zoster‑related eye inflammation (keratitis)?

Zoster‑related eye inflammation, most often called herpes zoster keratitis, is an infection of the cornea (the clear front surface of the eye) that occurs after reactivation of the varicella‑zoster virus (VZV). VZV is the same virus that causes chickenpox in childhood and shingles (herpes zoster) later in life. When the virus re‑emerges in the ophthalmic branch of the trigeminal nerve, it can spread to ocular structures, leading to inflammation, ulceration, and scarring of the cornea.

Keratitis caused by VZV can range from mild, transient redness to severe, sight‑threatening disease. Prompt recognition and treatment are essential to preserve vision and reduce complications such as glaucoma, cataract, or permanent corneal opacity.

Sources: Mayo Clinic, CDC, National Eye Institute (NEI).

Common Causes

The underlying event is always VZV reactivation, but several factors increase the likelihood that the virus will involve the eye.

• Shingles (herpes zoster) affecting the ophthalmic division (V1) of the trigeminal nerve
• Advanced age – risk rises sharply after 50 years.
• Immunosuppression – HIV/AIDS, organ transplant, chemotherapy, or long‑term steroid use.
• Chronic diseases – diabetes mellitus, chronic lung disease, or malignancy.
• Previous ocular trauma or surgery – corneal grafts, cataract extraction, LASIK.
• Contact lens wear – especially if hygiene is poor.
• Dry eye syndrome – reduced tear film may allow viral spread.
• Systemic stressors – severe illness, fever, or major surgery can trigger viral reactivation.
• Vaccination status – lack of shingles vaccine (Shingrix) increases risk.
• Genetic susceptibility – certain HLA types have been linked to more severe VZV eye disease.

Associated Symptoms

Patients with zoster‑related keratitis often present with a combination of ocular and systemic signs.

• Eye redness (hyperemia) and watering
• Severe eye pain or a deep, burning sensation
• Blurred or decreased vision
• Photophobia (sensitivity to light)
• Foreign‑body sensation or gritty feeling
• Patchy corneal opacity or ulceration visible on slit‑lamp exam
• Hutchinson’s sign – vesicular rash on the tip of the nose or upper lip, indicating V1 involvement
• Fever, malaise, or headache (especially when shingles is active elsewhere on the face)
• Tearing or discharge that may be clear or slightly mucoid

When to See a Doctor

Because corneal involvement can rapidly threaten vision, any of the following warrants immediate medical evaluation:

• Sudden onset of eye pain with redness and visual blur
• Presence of a shingles rash on the forehead, scalp, or around the eye
• Persistent photophobia that interferes with daily activities
• Seeing “spots,” “floaters,” or a halo around lights
• History of recent shingles, especially if you have underlying immunosuppression

If you notice any of these, schedule an urgent appointment with an ophthalmologist or go to the emergency department.

Diagnosis

Diagnosing zoster‑related keratitis combines a thorough history, visual‑function testing, and specialized eye examinations.

Clinical evaluation

• History taking – Recent shingles rash, vaccination status, immune‑system disorders.
• Visual acuity test – Determines how much vision is affected.
• Slit‑lamp biomicroscopy – Allows the eye doctor to see corneal lesions, dendritic or geographic ulcers, stromal infiltrates, and associated inflammation.
• Fluorescein staining – Drops of fluorescein dye highlight corneal defects under a blue light.
• Fundoscopic exam – Checks for posterior segment involvement (e.g., retinitis, optic neuritis).

Laboratory & imaging

• Polymerase chain reaction (PCR) of tear film or corneal scrapings – Confirms VZV DNA when the diagnosis is unclear.
• Viral cultures – Less commonly used, but can differentiate VZV from herpes simplex virus (HSV).
• Anterior segment optical coherence tomography (AS‑OCT) – Provides cross‑sectional images of corneal thickness and edema.
• Serology – May show elevated VZV IgM in acute infection, but not routinely required.

Early diagnosis is key; treatment initiated within 72 hours of symptom onset yields the best visual outcomes.

Treatment Options

Management involves antiviral therapy, anti‑inflammatory agents, and supportive eye care. Treatment is usually coordinated by an ophthalmologist.

Antiviral medications

• Oral valacyclovir 1 g three times daily for 7–10 days (first‑line for most patients).
• Acyclovir 800 mg five times daily – an alternative when valacyclovir is unavailable.
• Famciclovir 500 mg three times daily – useful in renal impairment.
• Intravenous acyclovir 10 mg/kg every 8 hours – reserved for severe keratitis, immunocompromised patients, or when oral therapy is not tolerated.

Antivirals reduce viral replication, shorten disease duration, and lower the risk of corneal scarring.

Corticosteroid eye drops

• Prescribed after antivirals are started to control stromal inflammation.
• Typical regimens: prednisolone acetate 1% drops 4–6 times daily, then tapered over 4–6 weeks.
• Close monitoring is essential to avoid secondary infection or increased intra‑ocular pressure.

Adjunctive therapies

• Lubricating eye drops (preservative‑free artificial tears) – relieve discomfort and promote healing.
• Bandage contact lenses – protect the cornea in cases of epithelial breakdown.
• Topical antibiotics (e.g., moxifloxacin) – prophylaxis against bacterial superinfection when an ulcer is present.
• Pain control – oral NSAIDs or acetaminophen; in severe cases, short courses of systemic steroids may be considered under specialist supervision.

Follow‑up care

Patients usually require weekly slit‑lamp examinations until the epithelium heals, then monthly checks for scarring or secondary glaucoma. Visual rehabilitation (e.g., rigid gas‑permeable lenses) may be needed for residual astigmatism.

Prevention Tips

Because the root cause is VZV reactivation, reducing the chance of shingles—and promptly treating shingles when it occurs—helps prevent ocular involvement.

• Get the shingles vaccine (Shingrix®) – recommended for adults ≥50 years, even if you’ve had chickenpox or a previous shingles episode.
• Maintain a healthy immune system – balanced diet, regular exercise, adequate sleep, and management of chronic diseases (diabetes, hypertension).
• Avoid unnecessary immunosuppression – discuss the risks of long‑term steroids or biologic agents with your physician.
• Promptly treat facial shingles – start oral antivirals within 72 hours of rash onset; inform your eye doctor if the rash is near the eye.
• Practice good eye hygiene – wash hands before touching eyes, avoid rubbing, and replace contact lenses as directed.
• Regular eye examinations for high‑risk individuals (elderly, diabetics, immunocompromised).

Emergency Warning Signs

Key Takeaways

Zoster‑related keratitis is a potentially sight‑threatening complication of shingles that affects the cornea. Early recognition, rapid antiviral therapy, and careful anti‑inflammatory management are essential for preserving vision. Vaccination against shingles, good systemic health, and prompt treatment of facial rashes dramatically lower the risk. Always consult an eye‑care professional at the first sign of eye pain, redness, or visual change, especially if you have a recent shingles rash or an immunocompromising condition.

References:

• Mayo Clinic. “Herpes Zoster Ophthalmicus.” Updated 2023.
• Centers for Disease Control and Prevention. “Shingles (Herpes Zoster) Vaccination.” 2022.
• National Eye Institute. “Keratitis.” 2022.
• American Academy of Ophthalmology. “Herpes Zoster Keratitis.” Clinical Practice Guidelines, 2021.
• World Health Organization. “Varicella‑zoster virus infections.” 2020.

```